Business Context and Reporting Period
Company: Innate Pharma S.A.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: April 2020
Date of Report: April 14, 2020
Principal Executive Office: 117 Avenue de Luminy, 13009 Marseille, France
This filing serves as a cover document for a press release dated April 14, 2020 (Exhibit 99.1). The registrant files annual reports under Form 20-F.
Key Financial Metrics
The provided filing text is a cover sheet and does not contain specific financial data. Consequently, the following metrics are not available in this document:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt Levels
- Liquidity Position
Note: The filing text does not provide a clear value for any financial metric.
Material Changes
No material changes regarding financial performance or operations are detailed in the cover sheet text. The filing references a press release (Exhibit 99.1) which likely contains the specific announcement, but the content of that release is not included in the provided input.
Guidance, Outlook, and Risks
The provided text contains no management commentary, forward-looking guidance, risk factors, contingencies, or descriptions of unusual items. These details would be contained within the referenced press release (Exhibit 99.1), which is not part of the input text.
Investor Verification Checklist
- Review the full text of the Press Release dated April 14, 2020 (Exhibit 99.1) to understand the specific event triggering this filing.
- Verify if the press release contains updates on clinical trial progress, regulatory approvals, or partnership agreements, as these are typical for Innate Pharma S.A.
- Check subsequent filings (e.g., Form 20-F or quarterly reports) for the actual financial impact of events announced in April 2020.
- Confirm the company's cash runway and liquidity status in the most recent audited financial statements, as this filing does not provide current cash figures.